由加州Second Sight公司开发的Prima系统是一种结合视网膜植入物和摄像眼镜的医疗设备，能够为患有晚期年龄相关性黄斑变性（AMD）的患者恢复视力。1该系统已于7月在欧洲获批，目前正在等待美国FDA的批准。1
该装置通过摄像眼镜采集约500万像素的视频信息，以每秒30帧的速率运行，随后由激光投影机发出880纳米波长的近红外光脉冲（不可见波长），将信号传输至包含378个像素的视网膜植入物。1植入物中的每个像素均配有一个电极和两个光伏电池，能够将光信号转化为神经刺激，从而实现视觉信息的传递。1
在接受培训后，超过80%的使用者能够利用该系统进行阅读、做填字游戏和使用手机等日常活动。1全球范围内，超过500万人患有年龄相关性黄斑变性。1
The Prima system, a medical device combining a retinal implant with camera glasses, can restore sight to patients with late-stage age-related macular degeneration (AMD).1 The system received European approval in July and is awaiting clearance from the U.S. Food and Drug Administration.1 Developed by California-based Second Sight Medical Products, Prima represents an advance for patients affected by this progressive eye condition.1
More than 80 percent of implant recipients regained functional vision after training, with abilities including reading, completing crossword puzzles, and using mobile phones.1 The device operates through a camera mounted on glasses that captures video at approximately 5 million pixels at 30 frames per second, while a laser projector emits near-infrared light pulses at 880 nanometers—invisible to the human eye—to stimulate the implanted electrode array.1 The retinal implant itself contains 378 pixels, each equipped with an electrode and two photovoltaic cells that convert the infrared light into electrical signals.1
Age-related macular degeneration affects more than 5 million people globally, making treatments like Prima important for addressing vision loss in affected populations.1
评论
还没有评论，欢迎留下第一条。